Lisata Therapeutics Acquired by Kuva Labs | Healthcare M&A Deal

Kuva Labs has agreed to acquire Lisata Therapeutics, a healthcare services other business in Delaware, for $0.001. Lisata Therapeutics, Inc. is the subject of a planned tender offer for its $0.001 par value common stock, CUSIP 128058302. Kuva Labs acquisitions in healthcare M&A are structured through Kuva Acquisition Corp., a direct wholly owned subsidiary of Kuva Labs Inc. The merger acquisition is a strategic acquisition and is governed by an Agreement and Plan of Merger dated March 6, 2026, with preliminary Schedule TO communications filed ahead of the tender offer commencement.